Compare DoorDash Inc (DASH) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Danaher Corporation — how do they compare? DoorDash Inc trades at $188.96 (market cap $82.60B), while Danaher Corporation trades at $199.47 (market cap $141.67B). The key difference: Danaher Corporation is the larger of the two by market cap, and Danaher Corporation pays a 0.8% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.
| DASH | DHR | |
|---|---|---|
Market Cap | $82.60B | $141.67B |
Sector | Consumer Cyclical | Health |
52-Week High | $281.74 | $242.05 |
52-Week Low | $146.60 | $161.91 |
Enterprise Value | $80.35B | $154.45B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $189.57, down 1.17% on the day, with a bullish technical outlook supported by moving averages and key resistance near $200. The company reported strong revenue growth to $13.72B in 2025 and achieved profitability with a net income margin of 6.81%. Recent partnerships, such as with Hungry Howie's and Urban Outfitters, highlight ongoing expansion in digital commerce and loyalty programs.
The stock presents a growth opportunity with a consensus price target of $237.92, implying 25% upside, but faces risks from intense competition and high valuation multiples. Earnings momentum is mixed, with a recent beat in Q1 2026 but misses in prior quarters. Investors should weigh robust cash flow generation against elevated P/E and EV/EBITDA ratios for a balanced view.
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
